WTI Crude


Brent Crude


Natural Gas




Heating Oil


Rotate device for more commodity prices

Alt Text

Oil Prices Lag In Spite Of Strong Inventory Draws

Global crude inventories are drawing…

Alt Text

Oil Futures Point To Higher Oil Prices

The contango in oil futures…

James Burgess

James Burgess

James Burgess studied Business Management at the University of Nottingham. He has worked in property development, chartered surveying, marketing, law, and accounts. He has also…

More Info

Could This Be One Of the Biggest Winners Of 2017’s Biotech Boom?

Medical scanner

The catalysts for a major biotech rally in 2017 are already multiplying—not least because of the Trump presidential victory—and one little-known company is poised for huge potential gains as it prepares to unveil a breakthrough medical device that could save the U.S. government tens of billions of dollars a year, and help prevent the 15 million strokes suffered annually around the world.

Some six million people die from stroke every year, while another 5 million people are rendered permanently disabled. In the U.S. alone, nearly 800,000 people suffer from strokes annually—and someone dies of a stroke every 4 minutes.

If ever there was a market for anything, it is tools to aid in early stroke detection, and this is exactly what CVR Medical (TSX:CVM.V; OTC:CRRVF) has been quietly and painstakingly working on for 10 years—and now it’s ready to charge out of the gate with its new, uniquely affordable technology.

A Lucrative New Era for Biotech

While Hillary Clinton had threatened the future of biotech companies by promising to go on the offensive against them, the unexpected victory of Donald Trump has analysts heralding a very bright and very lucrative new era for biotech. Speaking to Forbes, Todd Hagopian, who manages two mutual funds through Marketocracy.com, noted that with the Republicans in control of the White House and Congress, biotech companies are set up for an extraordinary comeback.

This is where the new barons are being made, with medical breakthroughs turning countless billions in new profits—and 2017 is set to be the strongest year ever.

Biotech companies are going to forge lucrative new frontiers this year, from cellular immunotherapies and liquid biopsies, to bioabsorbable stents and CVR’s Carotid Stenotic Scan (CSS), which detects stenosis within the Carotid Arteries—a serious risk factor in stroke.

We are also seeing major gains this year by cellular immunotherapies reporting 90 percent remission rates for acute lymphoblastic leukemia (ALL). This should go before the FDA this year and could trigger a wave of approvals for other blood cancers and lymphomas, and could eventually replace chemotherapy. Among many other positive developments in recent years, in December 2014, Amegen (NYSE:AMGN) won FDA approval for immunotherapy Blincyto, and large-cap AstraZeneca (NYSE:AZN) is also poised for major gains in redefining cancer treatment.

Liquid biopsies, or blood tests that uncover signs of actual DNA or cell-free circulating tumor DNA (ctDNA), could prove to be a revolutionary cancer test with annual sales forecast to be $10 billion. Cancer Genetics, Inc. (NASDAQ:CGIX) now has five programs to develop and validate multi-market liquid biopsy tests. And bioabsorbable stents, approved in the U.S. in July for the first time, have an amazing market potential approaching $2 billion in six years, with this year the critical juncture. Prominent North American players in this market include Abbott (NYSE:ABT) and Reva Medical Inc. (ASX:RVA).

It’s the perfect time for a small-cap company of top-notch professionals like CVR to release a new medical device that everyone is desperate for—from medical professionals, to insurance providers, to the billions of people who suffer a stroke every year.

3 Reasons to Keep a Close Eye on CVR Medical in the coming months:

1. The Market is Desperate for Affordable Stroke Solutions

When every second counts for a stroke sufferer, and current diagnostics take as long as three hours, CVR’s breakthrough Carotid Stenotic Scan (CSS) could potentially make the difference between life and death for millions because Carotid Artery Disease is the leading indicator of stroke.

It only takes on average 2 minutes, and the price tag on the device makes it affordable for providers and payers.

With strokes coming in as the second leading cause of death globally for people over the age of 60, and the fifth leading cause of death for people aged 15-59, a new technology that can deliver early detection of the leading indicator of stroke is beyond critical.

According to the CDC, early action is urgent for survival, and only 38 percent of stroke sufferers even recognize they are having a stroke in time to receive effective emergency intervention.

When you further consider that someone dies from a stroke every 4 minutes, CVR’s technology could end up being the most explosive thing on the medical scene in decades.

Let’s put this into perspective: In the same way that 3D seismic imagery revolutionized the oil and gas industry, letting explorers and producers find the sweet spots to drill in, CVR’s CSS technology plans to revolutionize stroke detection.

Until now, there has been no cost-effective way to screen for Carotid Artery Stenosis, which leads to Ischemic strokes—the most common type of stroke, which represent over 80 percent of strokes and cost the U.S. government alone tens of billions of dollars a year.

2. Affordable Answer to a Multi-Billion-Dollar Problem

CVR Medical’s CSS detects stenosis within the Carotid Arteries, potentially offering patients and caregivers a device for early detection in a quick and repeatable manner. Unlike other comparative modalities, the CSS was designed to function without the assistance of a certified technician. These three facts combine to create one of the potentially biggest—and most lucrative--phenomena in recent medical equipment market history.

CVR invested $23 million in its breakthrough technology, with early stage clinical trials complete and now headed toward pivotal trials, eyeing the potential for immediate profitability, with possible U.S. sales alone up to 400,000 devices annually at $49,000 each. When you talk globally, the numbers are staggering.

The CSS makes a connection between fluid flow and sub-sonic frequencies to detect arterial disease or blockage. Blood flowing through the carotid arteries produces wave patterns which are shaped and altered by the presence of irregularities on the inner artery walls. CVR’s advanced technology captures these wave patterns and analyzes them mathematically with patented algorithms. After a brief test, the analysis is complete, offering a way to potentially identify those at risk of a stroke and arming the healthcare provider with the information necessary to prevent the deadly event.

Coming in at $49,000 per unit, compared to up to $2.5 million for existing technology.

Additionally, some existing technologies are invasive and, due to cost, not accessible to many. CVR’s CSS is positioned to potentially fill this current gap. Once available, the CSS technology stands to save the U.S. government up to $34 billion a year, the current cost of strokes annually in the U.S. according to the CDC.

For investors, medical providers, insurers, and the public at large, the secondary benefit is that this new innovation has a price tag that renders testing up to 50 times cheaper than many tools on the market today.

3. The Final Phase Before Breakout

We are now right at the end-game here for this medical breakthrough, and the market impact could be quite dramatic.

After investing $23 million into R&D and keeping quiet about their findings and results for 10 years—CVR is at a critical junction where investment could soon to into significant profit. The company is just coming out of the early stage of clinical trials and is about to enter pivotal trials—and this is where the window of opportunity lies for investors.

What everyone should be keeping a close eye on right now is the release of the preliminary clinical report very soon, and then the full clinical report roughly 4-8 weeks later. Once they have this, it goes to the FDA to prove safety and efficacy and then market clearance and delivery.

And CVR is confident about the final round of clinical trials and FDA approval.

Where the big picture gets even better is the guaranteed market, and the costs. CVR’s all-in costs are less than half the sales costs—so the company is expecting high profitability right out of the gate, and it’s got manufacturing lined up already, just waiting for the final hurdles to be cleared.

The market potential here is some 235,000 medical offices—just in the U.S., and just for starters. If you do that math at just one device per office, the revenue is potentially staggering. But what investors really like to hear is that it won’t stop here: CVR’s breakthrough early detection stroke technology is only the beginning of series of breakthrough medical devices this company has in the works.

The era of biotech is here, and by all accounts, the political environment will welcome it with open arms, and the market has never been hungrier. At the center of it all, we have CVR—and hopefully very soon, an answer to a needless death every four minutes.

By James Burgess of Oilprice.com



PAID ADVERTISEMENT. This communication is a paid advertisement and is not a recommendation to buy or sell securities. Oilprice.com, Advanced Media Solutions Ltd, it’s owners, managers, employees, and assigns (collectively “The Company”) has been paid by a third party to disseminate this communication. This compensation is a major conflict with our ability to be unbiased, more specifically:

This communication is for entertainment purposes only. Never invest purely based on our communication. Gains mentioned in our newsletter and on our website may be based on end-of- day or intraday data. If we own any shares we will list the information relevant to the stock and number of shares here. We have been compensated by CVR Medical Corp to conduct investor relations advertising and marketing for [CVM.V]. Oilprice.com receives financial compensation to promote public companies.  This compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only.  We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates will liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices.  Any non- compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts experience a large increase in volume and share price during the course of investor relations marketing, which often end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.

We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our communications and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, The Company often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications.

DISCLOSURE. The Company does not make any guarantee or warranty about what is advertised above. The Company is not affiliated with, any specific security. While the Company will not engage in front-running or trading against its own recommendations, The Company and its managers and employees reserve the right to hold possession in certain securities featured in its communications. Such positions will be disclosed AND will not purchase or sell the security for at least two (2) market days after publication.

NOT AN INVESTMENT ADVISOR. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.

INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you agree to the terms of this disclaimer, including, but not limited to: releasing The Company, its affiliates, assigns and successors from any and all liability, damages, and injury from the information contained in this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.

FORWARD-LOOKING STATEMENT.  As defined in the United States Securities Act of 1933 Section 27(a), as amended in the Securities Exchange Act of 1934 Section 21(e), statements in this communication which are not purely historical are forward-looking statements and include statements regarding beliefs, plans, intent, predictions or other statements of future tense.

PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell securities. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results


All trades, patterns, charts, systems, etc., discussed in this message and the product materials are for illustrative purposes only and not to be construed as specific advisory recommendations. All ideas and material presented are entirely those of the author and do not necessarily reflect those of the publisher. No system or methodology has ever been developed that can guarantee profits or ensure freedom from losses. No representation or implication is being made that using the methodology or system will generate profits or ensure freedom from losses. The testimonials and examples used herein are exceptional results, which do not apply to the average member, and are not intended to represent or guarantee that anyone will achieve the same or similar results.

AFFILIATES. Some or all of the content provided in this communication may be provided by an affiliate of The Company. Content provided by an affiliate may not be reviewed by the editorial staff member. Our affiliates may have their own disclosure policies that may differ from The Company’s policy.

TERMS OF USE. By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here http://oilprice.com/terms-and-conditions If you do not agree to the Terms of Use http://oilprice.com/terms-and-conditions, please contact Oilprice.com to discontinue receiving future communications.

The information contained herein may change without notice.

Back to homepage

Leave a comment

Leave a comment

Oilprice - The No. 1 Source for Oil & Energy News